

NEURO-ONCOLOGY

Volume 10 Issue 4 • August 2008 • 539–646

539 Editorial: Impact Factor Grows, Thanks to Hard-Working Reviewers

W. K. Alfred Yung

Basic and Translational Investigations

540 Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas

Ahmed Idbaih, Emmanuelle Crinière, Yannick Marie, Audrey Rousseau, Karima Mokhtari, Michèle Kujas, Younas El Houfi, Catherine Carpentier, Sophie Paris, Blandine Boisselier, Florence Laigle-Donadey, Joëlle Thillet, Marc Sanson, Khê Hoang-Xuan, and Jean-Yves Delattre

548 The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222V) influences overall survival of patients with glioblastoma multiforme

Michael Linnebank, Alexander Semmler, Susanna Moskau, Yvo Smulders, Henk Blom, and Matthias Simon

553 Genetic variation in insulin-like growth factors and brain tumor risk

Stefan Lönn, Nathaniel Rothman, William R. Shapiro, Howard A. Fine, Robert G. Selker, Peter M. Black, Jay S. Loeffler, Amy A. Hutchinson, and Peter D. Inskip

Clinical Investigations

560 Primary central nervous system lymphoma in Japan: Changes in clinical features, treatment, and prognosis during 1985–2004

Yuta Shibamoto, Hiroyuki Ogino, Gen Suzuki, Mitsuhiro Takemoto, Norio Araki, Koichi Isobe, Emiko Tsuchida, Katsumasa Nakamura, Masahiro Kenjo, Kazunori Suzuki, Masako Hosono, Sunao Tokumaru, Shun-ichi Ishihara, Eriko Kato, Noriko Ii, and Naofumi Hayabuchi

569 A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood

Regina I. Jakacki, Allan Yates, Susan M. Blaney, Tianni Zhou, Robert Timmerman, Ashish M. Ingle, Lynda Flom, Michael D. Prados, Peter C. Adamson, and Ian F. Pollack

577 Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and *cis*-retinoic acid in children with diffuse intrinsic pontine glioma

Nongnuch Sirachainan, Samart Pakakasama, Anannit Visudithbhan, Surang Chiamchanya, Lojana Tuntiyatorn, Mantana Dhanachai, Jiraporn Laothamatas, and Suradej Hongeng

583 Prediction of volumetric change in the “triple ring” caused by glioma I-125 brachytherapy

Jenő Julow, Zsuzsa Kolumbán, Árpád Viola, Tibor Major, and Géza Kolumbán

593 Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1

Victor-F. Mautner, Florence A. Asuagbor, Eva Dombi, Carsten Fünsterer, Lan Kluwe, Ralf Wenzel, Brigitte C. Widemann, and Jan M. Friedman

599 Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: Final results of BSG 98 prospective trial

Didier Frappaz, Matthias Schell, Philippe Thiesse, Perrine Marec-Bérard, Carmine Mottolese, David Perol, Christophe Bergeron, Thierry Philip, Anne Claire Ricci, Sophie Galand-Desme, Alexandru Szathmari, and Christian Carrie

608 Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas

Stuart A. Grossman, Kathryn A. Carson, Surasak Phuphanich, Tracy Batchelor, David Peereboom, L. Burt Nabors, Glenn Lesser, Fredrick Hausheer, and Jeffrey G. Supko, for the New Approaches to Brain Tumor Therapy CNS Consortium

617 Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma

Surasak Phuphanich, Kathryn A. Carson, Stuart A. Grossman, Glenn Lesser, Jeffrey Olson, Tom Mikkelsen, Serena Desideri, and Joy D. Fisher for the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium

Reviews

624 What is the risk of intracranial bleeding during anti-VEGF therapy?

Craig P. Carden, James M.G. Larkin, and Mark A. Rosenthal

631 Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium

Susan M. Chang, Kathleen R. Lamborn, John G. Kuhn, W.K. Alfred Yung, Mark R. Gilbert, Patrick Y. Wen, Howard A. Fine, Minesh P. Mehta, Lisa M. DeAngelis, Frank S. Lieberman, Timothy F. Cloughesy, H. Ian Robins, Lauren E. Abrey, and Michael D. Prados; North American Brain Tumor Consortium

643 Letter to the Editor

Patrick Beauchesne

644 Society News

Oliver Bögl

